New Treatment for Vitiligo and Celiac Disease -TEV-408, an IL-15–Targeting Monoclonal Antibody

 A Novel Immunomodulatory Strategy for Vitiligo and Celiac Disease

Abstract

Vitiligo and celiac disease are chronic autoimmune disorders affecting different organ systems yet sharing overlapping immunopathogenic mechanisms. Accumulating evidence identifies interleukin-15 (IL-15) as a central driver of pathogenic immune memory and tissue-specific inflammation in both conditions. TEV-408 is an investigational fully human monoclonal antibody designed to neutralize IL-15 signaling and thereby interrupt disease-sustaining immune circuits. This article provides an integrated overview of the biological rationale underlying IL-15 inhibition, the clinical development status of TEV-408, its differentiation from existing therapeutic approaches, and its emerging investment and market potential. Collectively, TEV-408 represents a potentially disease-modifying intervention with implications for multiple immune-mediated disorders.

Keywords: TEV-408; interleukin-15; vitiligo; celiac disease; monoclonal antibody; autoimmunity

---

1. Introduction

Vitiligo and celiac disease are immune-mediated conditions characterized by chronic tissue damage driven by dysregulated adaptive immune responses. In vitiligo, melanocytes are selectively destroyed by autoreactive T cells, leading to progressive depigmentation of the skin. In celiac disease, gluten exposure triggers an inflammatory cascade that results in villous atrophy and impaired intestinal absorption. Despite advances in immunology, therapeutic options for both diseases remain limited, particularly with respect to systemic, disease-modifying interventions.

Recent immunological research has highlighted interleukin-15 (IL-15) as a pivotal cytokine sustaining pathogenic immune memory and cytotoxic effector responses in both disorders. Consequently, IL-15 blockade has emerged as a promising therapeutic strategy. TEV-408, a monoclonal antibody targeting IL-15, is currently under clinical investigation for both vitiligo and celiac disease, positioning it at the intersection of dermatology, gastroenterology, and translational immunology.

---

2. The Role of IL-15 in Autoimmune Pathogenesis

IL-15 is a pleiotropic cytokine essential for the survival, activation, and proliferation of natural killer (NK) cells and CD8⁺ memory T lymphocytes. Unlike many inflammatory cytokines, IL-15 is particularly important for maintaining tissue-resident immune memory, a feature increasingly recognized as a driver of chronic and relapsing autoimmune disease.

In vitiligo, IL-15 supports the persistence of resident memory T cells in the skin, which remain poised to re-initiate melanocyte destruction even after apparent clinical improvement. These cells are resistant to conventional immunosuppressive therapies, contributing to disease chronicity and relapse. Similarly, in celiac disease, IL-15 is upregulated in the intestinal epithelium in response to gluten exposure, where it promotes cytotoxic lymphocyte activation and epithelial cell death.

The convergence of IL-15–dependent immune mechanisms across these diseases provides a strong biological rationale for targeted IL-15 inhibition as a means of disrupting disease-sustaining immune circuits rather than merely suppressing downstream inflammation.

---

3. Mechanism of Action of TEV-408

TEV-408 is a fully human monoclonal antibody that binds IL-15 with high affinity, preventing its interaction with the IL-15 receptor complex and thereby inhibiting downstream signaling. Through selective IL-15 neutralization, TEV-408 aims to achieve targeted immunomodulation without inducing broad immunosuppression.

Preclinical studies have demonstrated that IL-15 blockade can eliminate pathogenic resident memory T cells and reverse depigmentation in vitiligo animal models. In early clinical studies involving healthy volunteers, TEV-408 showed evidence of on-target biological activity, including reductions in circulating IL-15 levels and IL-15–dependent immune cell populations, while preserving overall immune function.

In vitiligo, this mechanism may enable durable repigmentation by removing the immune memory responsible for melanocyte destruction. In celiac disease, IL-15 inhibition is expected to attenuate gluten-induced intestinal inflammation and epithelial damage, potentially offering protection against inadvertent gluten exposure.

---

4. Clinical Development Status

The clinical development of TEV-408 follows a multi-indication strategy:

• Phase 1: Completed in healthy volunteers, demonstrating favorable safety, tolerability, and pharmacodynamic target engagement.

• Vitiligo: Currently in Phase 1b clinical evaluation, focusing on safety and biological activity in affected patients.

• Celiac Disease: Advanced to Phase 2a, assessing the ability of TEV-408 to reduce gluten-induced intestinal injury and clinical symptoms.

Importantly, the U.S. Food and Drug Administration (FDA) has granted TEV-408 Fast Track designation for celiac disease, reflecting the substantial unmet medical need and absence of approved pharmacological therapies. Initial patient-level data from ongoing trials are anticipated in 2026.

---

5. Differentiation from Existing Therapeutic Approaches

Current vitiligo treatments—such as topical corticosteroids, calcineurin inhibitors, phototherapy, and topical Janus kinase (JAK) inhibitors—primarily address local inflammation and are limited in scope, particularly for patients with extensive disease. No approved systemic therapy directly targets the immunological memory underlying vitiligo pathogenesis.

Similarly, celiac disease management relies almost exclusively on lifelong adherence to a strict gluten-free diet. While effective for many patients, dietary therapy does not address the underlying immune dysregulation and offers no pharmacological safeguard against accidental gluten exposure.

TEV-408 differentiates itself by targeting a core immunological driver shared across both diseases. By intervening upstream in the inflammatory cascade, IL-15 blockade holds the potential to modify disease course rather than simply controlling symptoms, positioning TEV-408 as a first-in-class therapeutic candidate.

---

6. Investment and Market Potential

The development of TEV-408 has attracted substantial financial backing, including a strategic investment agreement with Royalty Pharma valued at up to USD 500 million. Such high-value partnerships are typically reserved for assets with strong scientific rationale and blockbuster-level commercial potential.

From a market perspective, vitiligo affects approximately 0.5–2% of the global population, while celiac disease has a prevalence of roughly 1%, with many cases remaining undiagnosed. Market analyses suggest that each indication could independently support annual revenues exceeding USD 1 billion if an effective disease-modifying therapy becomes available.

Moreover, given IL-15’s involvement in additional autoimmune and inflammatory disorders, TEV-408 may offer future opportunities for indication expansion, further amplifying its long-term commercial value.

---

7. Conclusion

TEV-408 represents a novel immunotherapeutic approach that targets IL-15–mediated immune memory, a fundamental mechanism driving chronic autoimmunity in both vitiligo and celiac disease. Supported by a robust biological rationale, early clinical validation, regulatory momentum, and strong investor confidence, TEV-408 stands out as a promising disease-modifying candidate. Ongoing and future clinical trials will be critical in determining whether IL-15 inhibition can translate into durable clinical benefit and reshape treatment paradigms across multiple autoimmune diseases.

---

References (APA 7)

Calcalist. (2025). Royalty Pharma to invest up to $500 million in Teva’s TEV-408 program.

Celiac Disease Foundation. (2024). TEV-408 (anti-IL-15 monoclonal antibody): Clinical trial overview.

Fierce Biotech. (2025). Teva advances anti-IL-15 antibody TEV-408 in vitiligo and celiac disease pipelines.

Sherman, S. (2025). Targeting immune memory cells in vitiligo: A new frontier. Ynet News. https://www.ynetnews.com/health_science/article/r1nc2f7bzg

Teva Pharmaceutical Industries Ltd. (2025). Pipeline and investor update: TEV-408.

Zhang, Y., & Zhang, S. (2023). Interleukin-15 signaling in autoimmune diseases. Journal of Immunology, 210(4), 455–463. https://doi.org/10.4049/jimmunol.2200456

Vitiligo ve Çölyak Yeni Tedavi - IL-15 Hedefli Monoklonal Antikor TEV-408

Vitiligo ve Çölyak Hastalığında Yenilikçi Bir İmmünomodülasyon Yaklaşımı

Özet

Vitiligo ve çölyak hastalığı, farklı organ sistemlerini etkileyen ancak ortak otoimmün mekanizmalar üzerinden gelişen kronik hastalıklardır. Son yıllarda interlökin-15 (IL-15) sitokininin bu hastalıkların patogenezinde merkezi bir rol oynadığı gösterilmiştir. TEV-408, IL-15’i nötralize etmeyi amaçlayan deneysel bir insan monoklonal antikorudur ve her iki hastalık için de potansiyel olarak hastalık-modifiye edici bir tedavi yaklaşımı sunmaktadır. Bu makale, TEV-408’in biyolojik mekanizmasını, klinik geliştirme sürecini, mevcut tedavilerden farklarını ve yatırım/pazar potansiyelini bütüncül bir çerçevede ele almaktadır.

Anahtar Kelimeler: TEV-408, interlökin-15, vitiligo, çölyak hastalığı, monoklonal antikor, otoimmünite

---

1. Giriş

Vitiligo ve çölyak hastalığı, bağışıklık sisteminin yanlış hedeflenmiş tepkileri sonucu gelişen otoimmün bozukluklardır. Vitiligo, melanositlerin bağışıklık aracılı yıkımı ile karakterize edilirken; çölyak hastalığı, gluten maruziyetine bağlı olarak ince bağırsak mukozasında gelişen inflamasyon ve villus atrofisi ile tanımlanır. Her iki hastalıkta da güncel tedaviler sınırlıdır ve hastalığın temel patofizyolojisini hedef alan onaylı sistemik biyolojik ajanlar bulunmamaktadır. Bu bağlamda IL-15 yolaklarının hedeflenmesi, otoimmün hastalık tedavisinde yeni bir paradigma olarak öne çıkmaktadır.

---

2. IL-15 ve Otoimmün Patogenez

IL-15, doğal öldürücü (NK) hücreler ve CD8⁺ bellek T hücrelerinin hayatta kalması ve proliferasyonu için kritik bir sitokindir. Otoimmün hastalıklarda IL-15’in aşırı ekspresyonu, patojenik bağışıklık hücrelerinin dokularda kalıcı hale gelmesine neden olmaktadır.

Vitiligoda IL-15, deride yerleşik bellek T hücrelerinin (resident memory T cells) devamlılığını destekleyerek melanositlere yönelik tekrar eden bağışıklık saldırılarını mümkün kılar. Çölyak hastalığında ise IL-15, gluten maruziyeti sonrası intraepitelyal lenfositlerin sitotoksik aktivitesini artırarak bağırsak epitelinde hasara yol açar. Bu ortak mekanizma, IL-15’i her iki hastalık için de cazip bir terapötik hedef haline getirmektedir.

---

3. TEV-408’in Etki Mekanizması

TEV-408, IL-15 sitokinine yüksek afiniteyle bağlanan ve onun biyolojik aktivitesini nötralize eden tam insan monoklonal antikorudur. IL-15 sinyalinin bloke edilmesiyle:

• Vitiligoda melanosit yıkımından sorumlu bellek T hücrelerinin dokuda kalıcılığı azalır,

• Çölyakta glutenle tetiklenen IL-15 aracılı inflamatuvar yanıt baskılanır,

• Bağışıklık sistemi genel olarak baskılanmadan, hedefe özgü bir immünomodülasyon sağlanır.

Hayvan modellerinde IL-15 blokajının vitiligoya bağlı depigmentasyonu tersine çevirebildiği gösterilmiştir. Sağlıklı gönüllülerde yapılan erken faz çalışmalarda ise TEV-408’in IL-15 seviyelerini düşürdüğü ve hedefe özgü biyolojik etki gösterdiği doğrulanmıştır.

---

4. Klinik Gelişim Süreci

TEV-408’in klinik geliştirme süreci çoklu endikasyon yaklaşımıyla ilerlemektedir:

• Faz 1: Sağlıklı gönüllülerde güvenlilik, tolere edilebilirlik ve hedefe bağlanma doğrulanmıştır.

• Vitiligo: Faz 1b aşamasında, hasta grubunda güvenlilik ve biyolojik etki değerlendirmesi sürmektedir.

• Çölyak Hastalığı: Faz 2a aşamasına ulaşılmış olup, gluten maruziyeti sonrası bağırsak hasarının azaltılması temel sonlanım noktasıdır.

ABD Gıda ve İlaç Dairesi (FDA), çölyak hastalığındaki karşılanmamış klinik ihtiyaç nedeniyle TEV-408’e Fast Track statüsü tanımıştır. İlk hasta verilerinin 2026 yılında açıklanması beklenmektedir.

---

5. Mevcut Tedavilerden Farkı ve Klinik Avantajları

Vitiligoda mevcut tedaviler (topikal kortikosteroidler, fototerapi ve topikal JAK inhibitörleri) genellikle sınırlı etki alanına sahiptir ve hastalığın sistemik doğasını hedeflemez. TEV-408 ise potansiyel olarak ilk sistemik ve hastalık-modifiye edici tedavi olma özelliği taşımaktadır.

Çölyak hastalığında ise günümüzde tek kabul edilen tedavi ömür boyu glutensiz diyettir. TEV-408, diyet dışı ilk hedefe yönelik biyolojik tedavi olma potansiyeli ile bu alanda paradigmatik bir değişim yaratabilir.

---

6. Yatırım ve Pazar Potansiyeli

TEV-408’in geliştirilmesi, biyofarmasötik alanda ciddi bir finansal destekle sürdürülmektedir. Royalty Pharma tarafından sağlanan ve 500 milyon ABD dolarına kadar ulaşabilen yatırım, ilacın ticari ve klinik potansiyeline duyulan güveni yansıtmaktadır.

Pazar analizleri, vitiligo ve çölyak endikasyonlarının her biri için yıllık 1 milyar ABD dolarını aşan satış potansiyeline işaret etmektedir. Ayrıca IL-15’in diğer otoimmün hastalıklardaki rolü göz önüne alındığında, TEV-408’in endikasyon genişletme potansiyeli de bulunmaktadır.

---

7. Sonuç

TEV-408, IL-15 hedefli mekanizması sayesinde vitiligo ve çölyak hastalığında mevcut tedavilerin ötesine geçen, hastalık-modifiye edici bir yaklaşım sunmaktadır. Klinik geliştirme sürecinin erken aşamalarında olmasına rağmen, güçlü biyolojik rasyonel, düzenleyici destek ve yüksek yatırım ilgisi, bu ilacı otoimmün hastalıklar alanında dikkatle izlenmesi gereken bir aday haline getirmektedir.

---

Kaynakça (APA 7)

Calcalist. (2025). Royalty Pharma to invest up to $500M in Teva’s TEV-408 program.

Celiac Disease Foundation. (2024). TEV-408 (anti-IL-15 antibody) clinical trial overview.

Fierce Biotech. (2025). Teva advances anti-IL-15 antibody TEV-408 in vitiligo and celiac disease pipelines.

Sherman, S. (2025). Targeting immune memory cells in vitiligo. Ynet News. https://www.ynetnews.com/health_science/article/r1nc2f7bzg

Teva Pharmaceutical Industries Ltd. (2025). TEV-408 investor and pipeline update.

Zhang, Y., & Zhang, S. (2023). Interleukin-15 signaling in autoimmune diseases. Journal of Immunology, 210(4), 455–463. https://doi.org/10.4049/jimmunol.2200456

Reduced Mortality Associated With Vitiligo

The chances of mortality could be low for patients with vitiligo, according to a recent study published in the Journal of Investigative Dermatology.

In the population-based cohort study, researchers explored the mortality of vitiligo as there is limited information about the risks of mortality among these patients. The researchers investigated all-cause and cause-specific mortality of patients with vitiligo compared with controls without vitiligo using a nationwide database.

Exploring vitiligo mortality in a national cohort would allow a greater understanding of the burden of the autoimmune disease and lead to a deeper understanding of its nature, the authors of the study claim.

The study included a total of 107,424 patients in Korea with vitiligo and 537,120 matched controls without vitiligo who were observed between 2002 and 2019. The mean age of included patients was ~48 years, and 39.61% were male.

Patients’ medical records were thoroughly analyzed and revealed that individuals with vitiligo experienced significantly reduced risks of mortality across a spectrum of diseases.

Of these findings, the risks associated with infectious, oncologic, hematologic, endocrine, neurologic, cardiovascular, respiratory, and renal/urogenital diseases were markedly lower in patients with vitiligo, the study revealed.

Previous studies have highlighted the co-occurrence of vitiligo with various autoimmune diseases, pointing to shared genetic alterations involved in immune activation and regulation. Specific immune responses have been identified as contributors to melanocyte destruction, authors shared.

What sets this study apart is that vitiligo seems to present a protective effect against mortality, particularly when it comes to infections, inflammation, and cancers.

Researchers suggest that the role of autophagy in vitiligo, a self-degradation process that regulates cellular homeostasis, could also relate to their findings.

Previous studies suggest that increased expression of autophagy markers in vitiligo skin may play a protective role against metabolic stress and external degenerative processes. In addition, autophagy's regulation of the innate immune system could provide defenses against viral infections.

The study also aligns with prior research indicating a reduced risk of malignancies in patients with vitiligo. In fact, the risk of internal malignancies, including cancers of the colon, rectum, ovary, and lung, was significantly decreased in individuals with vitiligo. The findings suggest that vitiligo may provide a form of immunity against cancer development.

Additionally, the study considers the role of treatments for vitiligo in contributing to reduced mortality. While there is no drug specifically approved for vitiligo, treatments such as phototherapy could have broader health implications.

For example, studies have suggested that ultraviolet B radiation, a component of phototherapy, may influence internal organs beyond the skin, offering benefits such as reducing the risk of atherosclerosis and improving blood pressure, the study mentioned.

However, there are certain limitations to the study which include the absence of information on disease severity and subtypes of vitiligo, potential unmeasured factors, and not having different populations observed.

The authors of the study believe the findings contribute toward the mortality risks associated with vitiligo, challenging previous beliefs about the outcomes of autoimmune conditions.

They added the unexpected protective effects observed in vitiligo patients open avenues for further research to unravel the underlying mechanisms and potential implications for patient management.

Reference

1. Ju HJ, Kang H, Han JH, Lee JH, Lee S, Bae JM. All-cause and cause-specific mortality among patients with vitiligo: a nationwide population-based study in Korea. J Invest Dermatol. 2023;S0022-202X(23)02481-8. doi:10.1016/j.jid.2023.07.007

Vitiligo, Causes,Symptoms, and Treatment

 

Vitiligo is a skin disorder in which smooth white areas called macules and patches appear on a person's skin. Generally starts on the hands for arms feet and face. Globally about 1% or so of the population has Vitiligo most people who have. Vitiligo will develop the condition prior to age 40 about half develop it before age 20. Vitiligo I may have a genetic component as the condition 10 Cimarron in families. Vitiligo is sometimes associated with other medical conditions including thyroid dysfunction.There is no way to determine if it'll I will spread or remain confined to one location. Types of Vitiligo do I go can be generalized which is the most common type when macules appear in various places on the body.

Segmental which is restricted to one side of the body or one area such as the hands or face mucosal what's your fax mucous membranes of the mouth and or the genitals. 

Focal which is a rare type in which the macros are in a small area and do not spread in a certain pattern within 1 to 2 years. Tricone which means that there is a white or color lacentre been an area of lighter pigmentation and then an area of normally colored skin.

Symptoms white patches on the skin are the main side of vitiligo these patches are more common in areas where the skin is exposed to the Sun the patches maybe on the hands feet arms face and lips other common areas for white patches are the armpits and groin where the leg meets the body around the mouth eyes nostrils Naval genitals rectal areas.

Causes although the causes of Vitiligo aren't completely understood there are a number of different theories autoimmune disorder the infected person's immune system May develop antibodies that destroyed their on a science genetic factors certain factors that may increase the chance of getting Vitiligo can be inherited.

About 30% of Vitiligo cases run in families neurogenic factors a substance that is toxic to melanocytes may be released at nerve endings in the skin self-destruction a defect in the Milana size causes them to destroy themselves Google are you I may also be triggered by certain events such as physical or emotional stress because none of the explanation seemed to completely account for the condition it's possible that a combination of these factors is responsible for vitiligo.

Diagnosis usually the white patches are easily visible on the skin but Healthcare Providers can use a Wood's lamp which shines ultraviolet or UV light onto the skin to help differentiate from other skin conditions. 

     Treatment repigmentation therapy therapy camouflage therapy surgery counseling prevention since no one knows for certain what causes Vitiligo no one can tell you how to prevent it in general it is smart forever to practice safe sun exposure habits and to take good care of your skin.

Jak Inhibitors

 

Disease where the immune system attacks of pigment cells are melanocytes in the body switch to white spots open and exposed areas such as the face and hands. Patient experienced increased quality of life despite affecting about 25 to 2% of the world's. Population know medications are FDA-approved to repigment in a liger who helped evaluate. 

What's the weather in cream to see if patients maybe were pigmented. About half the patients who received the highest dose of the Medicine Group Higgins 75% or more on the face significant number of patients also repugnant at on the body as well. He should serve as smart as early as 8 weeks after starting treatment. At the top of this medicine was well-tolerated with the table for safety profile it is currently being tested in a phase 3 Program. Hopefully become the first medicine that will be approved to treat vitiligo.

What is Vitiligo

 

Vitiligo likely meaning blemish is a non contagious skin condition that is defined by patches of Discoloration or deep pigmentation. The vitiligo can affect any race or ethnicity. It tends to be more noticeable in people with darker skin Like Canadian fashion model Winnie Harlow. 

Given the effect on a person's appearance, pigment loss can really impact a person's quality of life. Which is made of a single layer of small cuboido to low column stem cells that continually divide and produce new caratinosites They continue to mature is they migrate up through the epidermal layers but the straighten baseley also contains another group of cells Melanosites which secrete the protein pigment or coloring substance called melanin Melanin is actually a broad term that constitutes several types of melanin found in people of differing skin color.

The skin is divided into three layers the epidermis dermis and hypodermis The hypodermist is made of fat and connective tissue that anchors the skin to the underlying muscle Just above is the dermis which contains hair follicles, nerves, and blood vessels and just above that the outer most layer of skin is the epidermis. The epidermis itself has multiple cell layers that are mostly caratinosites which are named for the keratin protein that they're filled with. Keratin is a strong fibers protein that allows caratinocytes to protect themselves from getting destroyed when you rub your hands through the sand at the beach Current assights start their life at the deepest layer of the epidermis called the straight and baseley or basil layer.

These sub types of melanin range in color from black to redish. To reddish yellow and their relative quantity and rate at which their metabolised define a person's skin color When karate sites are exposed to the sun they send a chemical signal to the melanosites which stimulates the melanosites into making more melanin The melanosites move the melanin into small sax called malanosomes and these get taken up by newly formed caratinocytes Which will later metabolize the melanin as they migrate into higher layers of the epidermis melanin then axes in natural sunscreen.

Because it's protein structure dissipates or scatters the UVB light which if left unchecked can damage the DNA in the skin cells inly to skin cancer. Melanice can also be found in the dermis at the base of the hair follicle And in the eye where the help color hair and the iris respectively. There's a loss of melanocytes or the absence of their function. Histologically having less melanin in the epidermis result in white deep pigmented patches these patches are classified by type There's nonsegmental vitiligo which is the more common type that affects any age group. And it occurs at various locations that are mirrored on both sides of the body.

There's also segmental vitiligo which mostly affects children And occurs in segments along a single spinal nerve typically only on one side of the body without crossing the midline The exact cause of melanocyte destruction isn't known But it does seem to be linked to both genetic and environmental triggers. In non-segmental vitilgo there seems to be an autoimmune element where immune cells attack the melanosites. Insegmental vitiligo there seemed to be neural factors. Where nerves released neurochemicals that damage the melanocytes. 

Other causes maybe that the melanosites get damaged by a build up of toxic metabolites Is they make melanin or in other metabolic pathways one interesting observation is called the cubner phenomenon. And that's when Vitiligo develops in skin soon after there's been a trauma like a cut abrasion or burn The main symptom of it a ligo is the irregular round or oval shaped patches of depigmentation appearing within normally pigmented skin The patches can range in size from millimeters to centimeters and can sometimes expand and merge with other patches over time The body hair and the iris may also be depigmented in affected areas Non-segmental vitiligo tends to affect the hands forearms, neck, scalp, feet, and face while segmental vitilgo tends to affect areas of skin near dorsal roots from the spinal cord.

Particularly in the face following the trigeminal nerve. The diagnosis of it a ligo is based on the appearance of D pigmented patches but a skin biopsy can also be done There are two main treatments. When the affected area is small, cosmetic cover up and topical immune suppressants can be applied directly to the skin. When the affected area is large systemic immune suppressant UV photo therapy skin bleaching Skin bleaching and in severe cases skin grafts can all be tried. Whatever the course of therapy sunscreen is recommended to prevent darkening of the skin areas immediately surrounding And contrasting the deep pigmentation areas and to reduce the risk of skin cancer.

Alright it's a quick vitiligo is a non contagious condition where destruction of melanosites and loss of melanin Leads to areas of deep pigmentation on the skin tends to affect the hands Arms, neck, scalp, feet, and face. Well, segmental vitiligo tends to affect the areas of skin near dorsal roots from the spinal cord Particularly in the face following the trigeminal nerve. For small areas, cosmetic cover up and topical immune suppressants can be used Areas systemic immune suppressants UV photo therapy skin bleaching and even skin grafts can be used as well Thanks for watching. If you're interested in a deeper dive on this topic take a look at us most.org where we have flashcards, question Gins and other awesome tools to help you learn medicine.

Vitiligo - Photothreapy

 

It's an autoimmune disease against the pigments within pigmentation. Science so the numbers will be the same for the pigments within then we'll be decreased we should fix all surfaces in the body including the skin and only coastal areas such as the mouth and the inner lining of the genital tract.

What causes the disease to start is still unclear but missions normally start having symptoms but the second or third decade of life because it's an autoimmune disorder is likely to have other autoimmune disorders as well. Keep in mind that fix skin is more prone to sunburns. We have for treatment we can use phototherapy which repigment melanocytes we can use tools to prevent further pigmentation in which layer of the skin do we have melanocytes.

Medical Treatment of Vitiligo

 

Skin discolorations such as vitiligo were known thousands of years ago. White spots caused by vitiligo and other disorders have caused a significant social disgrace throughout history and today for those who have been disfigured due to these pigmentary disorders. Treatments have been desperately sought with only partial success. Recent developments suggest that vitiligo and other pigment disorders may soon be cured.

Leukoderma, white spots ve vitiligo

Perfect, flawless skin color is desired by everyone for its beauty and attractiveness. However, like all biologic systems, pigmentation can be abnormal. There can be dark spots or light spots, both of which are disfiguring. These problems have caused distress to people for millennia. Already in 1500 to 1000 BCE, Indian writers described “kilas” and “palita,” translated as white or yellowish white spots.

The Ebers Papyrus describes people with white spots. In these early writings, the precise condition being described is not known, although leprosy and vitiligo are just two of many possible candidates. There are numerous references to white spots in the Old Testament. Typically these were considered leprosy but it is plausible that much of what was considered to be leprosy was vitiligo or other disorders of skin color.

In the Far East prayers known as Makatominoharai dating from 1200 BCE recognized white skin, possibly vitiligo. In the sixteenth century, Hieronymus Mercurialis6 published his book on diseases of the skin. In it he devotes an entire chapter, entitled “On Leuce and Alphos,” to disorders of abnormal skin color.

He cites early Arabic, Greek, and Latin scholars about white spots and notes that the word “…‘vitiligo’ is a Latin word derived from either ‘vitium’ (blemish) or ‘vitulum’ (small blemish)…” The word vitiligo might have been first used by Celsus. Mercurialis suggests that phlegm accumulating under the skin was the source of leukoderma, a theory that he confirms from the writings of “…divine Plato…that white phlegm has two effects in the body….if it begins to vent through the exterior of the body, it will cause …vitiligo.”

Herodotus in Greece noted white spots on foreigners and suggested they be banished immediately, their having sinned against the sun. In China and Korea, writers discussed white spots and white skin. In Korea vitiligo and other pigmentary disorders, such as nevus depigmentosus or tinea versicolor, were described in Doney Bogam, published in the seventeenth century.

A portrait of Chang-Myeong Song, a high ranking official of the Yi dynasty of Korea, was painted about this time that shows the typical depigmentation of vitiligo. In the seventeenth century, William Byrd described “An Account of a Negro-Boy that is, dappel’d in several places of his Body with White Spots.” The depigmentation began at age 3 years and continued to spread. Byrd conjectures that in time the boy would become all white. The leukoderma was obviously mysterious in origin.

Study skin, color, white spots

Skin color was a mystery until modern times after the invention of the microscope, the techniques of biopsy, and the discovery of histochemical stains. Before the seventeenth century, the origin of skin color was based on myths, folklore, and religious theories. Explanations attempted to explain the origin of dark skin color, not why some skin was very light. Jean Roland in separated the epidermis from the dermis of a black individual.

He was able to observe the upper layer of skin (epidermis) was pigmented, the lower dermal layer not pigmented. He proposed that sunlight and heat caused dark skin, a theory that might explain dark skin at the equator but not why Europeans remained white when traveling to southern climes. Another scientist, Thomas Browne, noted this discrepancy and decided skin color was a genetic trait carried within the sperm.

Theories about the mechanism for production of skin color came and went. Many famous investigators all studied skin color usually in deeply pigmented Ethiopians, often on cadavers but occasionally in living subjects. However, without proper instruments and techniques, the origins of pigmentation remained a mystery. More mysterious back then were the mechanisms for loss of skin color. Benjamin Rush suggested that black skin of Negroes was a form of leprosy and that vitiligo was an indication of spontaneous cure.

Skin Color and Melanin System

 

The skin is a complex organ system capable of going through a wide variety of color changes. Normal skin color arises from a mixture of red, blue, yellow and brown colored pigments. In normal skin, melanin is the main pigment or color determinant, giving a color ranging from very light tan to dark brown or black, depending on the amount of melanin in the epidermis. It can be given a yellow color by carotenoids, red by oxygenated hemoglobin in capillaries, and blue by reduced hemoglobin in dermal venules and pigment in the dermis. Melanin is synthesized by a special cell, melanocyte, which is a dendritic cell located in the basal layer of the epidermis, but some melanocytes higher in the epidermis and a few in the dermis.

The melanin pigment system consists of millions of such melanocytes, each of which is functionally associated with 36 keratinocytes; This cluster of keratinocyte and associated melanocyte is referred to as the "epidermal melanin unit", which appears to be a structural and functional entity. Within each working melanocyte, melanin is synthesized and packaged in special pigment organelles called "melanosomes". The dendritic processes of melanocytes project between keratinocytes so that a single melanocyte supplies melanosomes to 36 keratinocyte groups.

Melanine migrate

These melanosomes migrate centrifugally through the dendritic processes of melanocytes and are then transferred to or captured by keratinocytes. Although the number of active epidermal melanin units per unit area varies considerably in various regions of human skin, the keratinocyte/melanocyte ratio remains constant. The epidermal melanin unit has been suggested to be the functional integrator of the multicellular melanin pigmentation system in humans and animals.

Although skin color can be conceptually thought of as a mixture of the colors red, blue, yellow, and brown above, racial differences in normal skin color and skin color are a function of the number, size, and distribution of melanin-laden organelles.

Melanosomes

It is the melanosomes that are distributed into the keratinocytes that give the skin its color. In the absence of disease, other color contributors play a minor or insignificant role. Therefore, in the absence of melanin, the skin remains essentially white, as in tyrosinase-negative albinism or vitiligo macules. Recent evidence that the movement of keratinocytes within the epidermis is more complex than originally thought is not inconsistent with the concept of the epidermal melanin unit.

Keratinocytes activite

Keratinocytes do not divide randomly in the germinal layer of certain types of human and mouse epidermis. Mitoses can also occur in suprabasilar keratinocytes. According to the epidermal proliferation unit concept, young basal cells divide and move peripherally in the epidermis before final division and formation of regular columns of cornified cells.

Each or several epidermal proliferative units can then be associated with a donor melanocyte. The study of the melanin-producing mechanism should be approached at five scientific levels: macromolecular (visual) - skin viewed as an organ system; multicellular (histological)-epidermal melanin unit; cellular-melanocytes as unicellular glands; subcellular (electron microscopic)- melanosome as a metabolic unit of melanogenesis; and macromolecular (biochemical)-tyrosinase, enzyme and melanoprotein, the end product of melanogenesis.

Types of melanin

 

There are three different types of melanin: eumelanin, pheomelanin, and neuromelanin. Eumelanin is the brown-black pigment of skin and hair and is most responsible for skin color. Phaeomelanin is a red-yellow pigment found in human hair. Neuromelanin is found in neurons of the central nervous system, adrenal medulla, and other areas of the chromaffin system.

Eumelanin

Eumelanin is a high molecular weight polymer whose exact molecular structure has not yet been determined, in part because eumelanin is insoluble in most solvents and resists most chemical changes and degradation.

Observations based on Raper's work with plant tyrosinases and modified by Mason led to the conclusion that melanin is a polymer composed of indole5,6-quinone units. However, the use of labeled antecedents showed that this was an oversimplification.

The ratio, molecular chain length, and molecular weight of the various subunits of eumelanin are still unknown. Blois et al. thinks that melanin is a highly disordered three-dimensional polymer joined by covalent bonds. Melanin has a free radical character associated with the semi-quinonoid form of 5,6-dihydroxyindole, which is highly stabilized by resonance through the conjugated polymer. Can act as a mild free radical quencher and also have some weak acid cation exchange abilities. Skin Melanin has specific absorption peaks at 3 and 6 J.L. only in the infrared region; however, it shows a broad absorption band between 200 and 2400 nm, which is not quite specific.

Phaeomelanin

Phaeomelanins are yellow and red sulfur-containing pigments found in mammalian hair. Unlike eumelanin, pheomelanin is soluble in dilute alkali. Pheomelanins, like eumelanin, are derived from tyrosine via dopaquinone. However, it is the interaction of cysteine ​​with dopaquinone at this level that results in the synthesis of pheomelanin. By adding 1,6 cysteine ​​to dopaquinone, 13-(5-S-cysteinyl-3,4-dehydroxyphenyl)alanine or 2-S-cysteinyldopa is formed. This is further oxidized to form pheomelanin. A minor product of the addition of 1.6 may be 2-S-cysteinyldopa.

Sulfhydryl compounds are involved in in vivo synthesis; indeed, under some experimental conditions, sulfhydryl compounds can induce pigment cells to produce yellow pigment. The interesting genetic control influencing the common pathway of eumelanin and pheomelanin synthesis is mirrored in the agouti mouse, which has only a few subapical pheomelanoms, the rest of which are eumelanogenic. Follicular melanocytes initially produce brown-black eumelanin, temporarily switch to yellow pheomelanin production, and soon revert to the original eumelanin synthesis.

Guinea pig studies have shown that melanosomes in red or yellow follicles are spherical, while those of black follicles are ellipsoidal. Various differences in biochemical behavior were observed between eumelanin and pheomelanin.

It has been shown that more sulfhydryl compounds, including glutathione and cysteine, are more incorporated into pheomelanogenic melanocytes and pheomelanin than eumelanic melanocytes and eumelanin. In the presence of sufficient reduced glutathione in vitro, only melanocytes that synthesize eumelanin in vivo produce pheomelanin. It has been suggested that the agouti band in the agouti mouse is derived from cyclically altered competition patterns by keratinocytes and melanocytes for substrate common to hair growth and melanogenesis.

Therefore, it was suggested that cyclical changes in the type of melanin synthesized might involve histochemical changes, not genetic intervention. Knisely et al. corroborating these findings with yellow (AY/a) samples in similar conditions and cultures of (A/A) agouti skin may be related to such histochemical factors not present in these systems.

Although cysteine ​​is an established substrate for pheomelanogenesis, cysteinyldopa and pheomelanin can be produced by eumelanogenic melanocytes. It has also become clear that there is a third melanocyte pigment called trichochrome, which has dopaquinone as a critical intermediate, such as eumelanin and pheomelanin. The factors that favor one final path over another remain unclear.

Neuromelanin

The trigeminal and dorsal root ganglia, substantia nigra, locus caeruleus, and pigmented nuclei of the basal ganglia contain cytoplasmic organelles containing a brown pigment called "neuromelanin." There seem to be significant differences between eumelanin and neuromelanin.

Since patients with oculocutaneous albinism have a normal amount of neuromelanin, it seems unlikely that neuromelanin is formed by the action of tyrosinase. There are other important differences between melanin and neuromelanin.

Pigment particles of the substantia nigra appear to have a higher electron density than melanosomes, a size of 0.5 to 2.5 f.L, a single limiting membrane, and the longitudinal or diagonal striations typical of eumelanin melanosomes. The presence of labeled tyrosine in the area of ​​pigmented granules in neurons convinced the researchers that tyrosine must be present.

The enzyme that catalyzes the hydroxylation of tyrosine to dopa is probably tyrosine hydroxylase and not the copper-requiring oxidase tyrosinase. Since tyrosine hydroxylase only catabolizes CNS tyrosine, disorders of eumelanin synthesis and CNS abnormalities should not be expected, and neuromelanin disorders (such as Parkinson's disease) should not be expected to have obligatory abnormalities of cutaneous eumelanogenesis.

Ginkgo biloba help protect melanocytes

Vitiligo is a common skin depigmentation disorder characterized by loss of functional melanocytes. Its pathogenesis is complex and oxidative stress plays a critical role in the development of vitiligo. Therefore, antioxidant therapy is a promising therapeutic strategy to prevent or even reverse the progression of depigmentation.

Ginkgo biloba extract has been confirmed to have protective effects on neurons against oxidative stress. In particular, several clinical studies have shown that patients with stable vitiligo achieve repigmentation after taking. However, the precise mechanism underlying the protective effects of against oxidative stress on melanocytes has not been fully elucidated.

In this study, we found that effectively protected melanocytes against oxidative stress-induced apoptosis and attenuated excessive reactive oxygen species (ROS) accumulation and lipid peroxidation by increasing the activity of antioxidative enzymes. Moreover, the antioxidative effect of was achieved by activating and its downstream antioxidative genes. In addition, interference of with siRNA abolished the protective effects of against oxidative damage on melanocytes. In conclusion, our study proves that can protect melanocytes.

Interfering with siRNA abolished the protective effects of against oxidative damage on melanocytes. In conclusion, our study proves that can protect melanocytes. Interfering with siRNA abolished the protective effects of against oxidative damage on melanocytes. In conclusion, our study proves that can protect melanocytes from oxidative stress caused by activating. Therefore, is hypothesized to be a potential therapeutic agent for vitiligo.

What should patients with vitiligo pay attention to in their diet?

Vitiligo patients should eat more tyrosine-rich foods, such as lean meat, eggs, various animal organs, milk, loofah, eggplant, carrots, peanuts, black sesame seeds, walnuts and other fresh vegetables and soy products.Eat less spicy, greasy and stimulating foods, and eat less foods with high vitamin C content, such as tomatoes, oranges, grapefruit, apricots, hawthorns, cherries, kiwis, strawberries, bayberry, etc. Eat as little or no food as possible.

How to effectively treat vitiligo?

This disease is one of the diseases that are easy to diagnose and difficult to treat, with a long course of treatment, and its treatment methods vary from person to person. At present, the combination of local and overall treatment is mainly adopted. 

1. Narrow-band ultraviolet rays: There are many treatment methods for vitiligo, and patients can choose a variety of treatment methods according to their own disease characteristics. Narrow-band ultraviolet (NB-UVB) with a wavelength of 311nm is currently the most commonly used method for the treatment of vitiligo at home and abroad. It can significantly promote the proliferation of melanocytes and the synthesis of melanin, activate tyrosinase activity, and inhibit skin dendrites. Immune function of T-shaped cells and T lymphocytes. It has the characteristics of high strength, quick effect, good curative effect, small adverse reactions, wide indications, etc. It will not cause pain to the human body, has less side effects, is also safe and effective for children's vitiligo, and can significantly improve The patient’s quality of life. Patients can be treated with a combination of narrow-band UVB and drugs.

2. Photochemotherapy

3. Autologous epidermal transplantation

4. Glucocorticoids include systemic medication and topical medication.

5. Traditional Chinese Medicine.

Some Food Restriction Tips for Vitiligo patients

1. Some food items like juicy fruits rich in vitamin C or ascorbic acid such as oranges and lemon, other fermented food items as curd, alcohol, Fish, red meat are to be avoided as they have harmful effect on vitiligo and can give rise to spreading of patches.

2. It has been seen that Turmeric slows down pigmentation rate & responsible for depigmentation and is good for fairness. So, turmeric application & raw intake has to be avoided in Vitiligo. Moreover it’s a great antiseptic.

3. Beetroot & Carrots actually helps in pigmentation. These can be helpful in faster pigmentation.

4. Almost 70% of Vitiligo patients suffer from Vitamin D3 deficiency. Taking Vitamin D3 supplement helps in control of spots. These also promote pigmentation along with Ayurvedic treatment.

5. Omega 3 capsules and diet should be completely restricted in Vitiligo as Omega 3 triggers Vitiligo spots.

6. Soda bi carbonate found in aerated drinks are found to be triggering Vitiligo and should not be taken.

7. Copper glassful water helps in pigment deposition over skin. It is helpful and should be taken daily at least one glassful.

8. Figs & Dates are copper rich and are helpful in pigmentation so these are recommended in Vitiligo.

9. Vitamin D3 & Vitamin B12 are seen helpful in vitiligo but they should be taken from vegetarian/organic sources only.

We understand that Diet restriction has much important role in Vitiligo & Leucoderma. Its treatment also requires food restriction for proper healing of patches. The diet restrictions chart mentioned below is much elaborated and will provide clear restriction list to Vitiligo patients

Relationship between vitiligo and psoriasis

USER QUESTION: I have vitiligo and recently noticed that I have psoriasis in my scalp. Thought it was dandruff for a while, but one of my doctor confirmed it’s psoriasis and it very mild.I have accepted vitiligo and shocked to know one more auto immune disorder. Any one else with me here? Please drop your stories Thanks a ton !

ANSWER: Psoriasis causes reddish skin texture and white scales.... alopecia areata causes similar white patches as vitiligo and patchy hair loss with scales.... Recheck one more time and take necessary treatment... Treatment is different for both... Note; both are auto immune disorder... Check your vitamin D, vitaminB12, Zinc, folic acid and copper...

If you lack take suppliments not for long time.. VitaminD is fat soluble.. You can't take for longer time... Vitamin b12 is water soluble so you can take for long period that does not cause any harm... Still you can give intervals..... For vitiligo take above mentioned suppliments Apply tacrolimus in the morning and show it for 10 mins in the morning sunlight..tacrolimus is not a steroid...

So not much side effects...once in 4 days In night you can use hydrocortisone 1% immunosuppressive steroid,,, it's class seven drug with least potent steroid... Side effects are less but still not advisable to use not more than 1 month... I hope this helps you.